#United States #Pleasanton #Clinical Development #Veeva #IQVIA

Strategic Partnership Between IQVIA and Veeva

In a significant move aimed at streamlining processes in the clinical development and commercial fields, IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) have announced a long-term partnership. Both companies have resolved all outstanding legal issues, creating a foundation for enhanced collaboration. As a result of this partnership, customers will have simplified access to the combined offerings of IQVIA and Veeva, integrating software, data, technology, and services efficiently.

Enhancing Commercial Solutions

The partnership is set to transform the commercial landscape. A key element is the agreement on Third-Party Access (TPA) for master data and software. This allows seamless usage of either IQVIA's or Veeva's data through customers' chosen software and services. Specific tools entering this synergy include Veeva Network for master data management (MDM), Veeva Nitro for analytics, and Veeva AI, allowing for IQVIA's data integration. Additionally, customers will leverage Veeva data in IQVIA's commercial products and services, participating in technology integration initiatives such as Services Partner Programs. These strategic alignments will expedite the TPA acquisition process, leading to smoother project workflows.

Advancements in Clinical Development

In the realm of clinical development, IQVIA's engagement in the Veeva CRO Clinical Data Partner program facilitates enhanced clinical trial executions using Veeva's Clinical Suite. This integration, which includes the construction of studies via Veeva EDC, positions customers to combine IQVIA's clinical data management expertise and technology solutions with Veeva's software capabilities. The combined strengths promise to accelerate processes like database creation, study lock, and data delivery, yielding faster outcomes for clinical trials.

Leadership Perspectives

Peter Gassner, founder and CEO of Veeva, expressed optimism about the partnership's potential, stating, "We are committed to facilitating smooth integration of products and services with IQVIA for the benefit of our shared customers and the industry as a whole. We anticipate that our partnership in clinical development and commercial fields will deliver significant value to our mutual clients."

Ari Bousbib, chairman and CEO of IQVIA, emphasized the advantages for customers, noting, "The partnership merges the best capabilities in information, AI, technology, and services for our clients. By utilizing Veeva’s platform, IQVIA customers can expedite clinical development, effectively launch therapies into the market, and increase patient access to innovative treatments."

Future Insights

Both companies are poised to unlock greater efficiencies and advancements in the industry landscape. As IQVIA continues to provide leadership in clinical research services, commercial insights, and healthcare intelligence, the integration of Veeva’s leading cloud-based solutions solidifies a robust future for health outcomes globally.

For further details on this partnership, interested parties can visit the dedicated sections on IQVIA's website or Veeva's site.

Conclusion

This strategic alliance not only paves the way for innovative solutions but also enhances the capabilities available to clients in both the clinical and commercial sectors. As both companies work towards maximizing value, the future looks promising for the healthcare and life sciences landscape, setting new standards for collaboration and service excellence.